Rabella Mireia, Grasa Eva, Corripio Iluminada, Romero Sergio, Mañanas Miquel Àngel, Antonijoan Rosa Mª, Münte Thomas F, Pérez Víctor, Riba Jordi
Servei de Psiquiatria, Hospital de la Santa Creu i Sant Pau, C/SantAntoniMaría Claret, 167, 08025 Barcelona, Spain; Departament de Farmacologia i Terapèutica, Universitat Autònoma de Barcelona 167, 08025 Barcelona, Spain.
Servei de Psiquiatria, Hospital de la Santa Creu i Sant Pau, C/SantAntoniMaría Claret, 167, 08025 Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain.
Neuroimage Clin. 2016 Jun 1;11:770-779. doi: 10.1016/j.nicl.2016.05.019. eCollection 2016.
Schizotypal personality disorder (SPD) is a schizophrenia-spectrum disorder characterized by odd or bizarre behavior, strange speech, magical thinking, unusual perceptual experiences, and social anhedonia. Schizophrenia proper has been associated with anomalies in dopaminergic neurotransmission and deficits in neurophysiological markers of self-monitoring, such as low amplitude in cognitive event-related brain potentials (ERPs) like the error-related negativity (ERN), and the error positivity (Pe). These components occur after performance errors, rely on adequate fronto-striatal function, and are sensitive to dopaminergic modulation. Here we postulated that analogous to observations in schizophrenia, SPD individuals would show deficits in self-monitoring, as measured by the ERN and the Pe. We also assessed the capacity of dopaminergic antagonists to reverse these postulated deficits.
We recorded the electroencephalogram (EEG) from 9 SPD individuals and 12 healthy controls in two separate experimental sessions while they performed the Eriksen Flanker Task, a classical task recruiting behavioral monitoring. Participants received a placebo or 1 mg risperidone according to a double-blind randomized design.
After placebo, SPD individuals showed slower reaction times to hits, longer correction times following errors and reduced ERN and Pe amplitudes. While risperidone impaired performance and decreased ERN and Pe in the control group, it led to behavioral improvements and ERN amplitude increases in the SPD individuals.
These results indicate that SPD individuals show deficits in self-monitoring analogous to those in schizophrenia. These deficits can be evidenced by neurophysiological measures, suggest a dopaminergic imbalance, and can be reverted by dopaminergic antagonists.
分裂型人格障碍(SPD)是一种精神分裂症谱系障碍,其特征为行为怪异或奇特、言语奇怪、存在奇幻思维、有异常的感知体验以及社交快感缺失。精神分裂症本身与多巴胺能神经传递异常以及自我监测的神经生理标记物缺陷有关,比如认知事件相关脑电位(ERP)中像错误相关负波(ERN)和错误正波(Pe)这样的低波幅。这些成分在执行错误后出现,依赖于适当的额纹状体功能,并且对多巴胺能调节敏感。在此我们推测,与精神分裂症的观察结果类似,SPD个体在自我监测方面会表现出缺陷,通过ERN和Pe来衡量。我们还评估了多巴胺能拮抗剂逆转这些假定缺陷的能力。
我们在两个单独的实验环节中记录了9名SPD个体和12名健康对照者的脑电图(EEG),他们在执行经典的用于行为监测的埃里克森侧翼任务时进行记录。参与者根据双盲随机设计接受安慰剂或1毫克利培酮。
服用安慰剂后,SPD个体对正确反应的反应时间较慢,错误后的校正时间较长,并且ERN和Pe波幅降低。虽然利培酮损害了对照组的表现并降低了ERN和Pe,但它却使SPD个体的行为得到改善且ERN波幅增加。
这些结果表明,SPD个体在自我监测方面表现出与精神分裂症患者类似的缺陷。这些缺陷可以通过神经生理学测量得到证实,提示存在多巴胺能失衡,并且可以被多巴胺能拮抗剂逆转。